Nutriband Inc. (NTRBW) Aandelenanalyse

Bedrijfsoverzicht

Nutriband Inc. is a specialized developer focused on creating a portfolio of transdermal pharmaceutical products within the United States market, with its primary focus currently placed on the lead product in development known as AVERSA fentanyl. This extended-release transdermal fentanyl product is designed to function as an abuse deterrent system, providing clinicians and patients with a specific therapeutic option for pain management while mitigating misuse risks. Although the company operates within the pharmaceutical sector and the broader healthcare industry, specific classifications for its exact sector and industry sub-sector are not explicitly defined in current public records. The scale of the enterprise is characterized by a market capitalization that is currently unlisted, alongside an annual revenue of $2.28 million and an employee count that remains undisclosed. These valuation and operational metrics indicate a small-cap or micro-cap entity operating with limited resources compared to large-cap pharmaceutical peers, suggesting a high-risk profile typical of early-stage biopharmaceutical companies that are still navigating the lengthy regulatory pathways required for product approval and commercialization.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $2.28 million, yet this top-line figure masks a significant operational deficit, evidenced by a net loss of $34,592,176 and an EBITDA of -$9,029,840. The substantial disparity between the $2.28 million in revenue and the -$34.6 million in net income reveals a cost structure that is heavily burdened by non-operating expenses or significant losses prior to interest and taxes, likely stemming from R&D expenditures, legal fees, or impairment charges common in clinical development stages. Free cash flow stands at -$2,588,350, which indicates that the company is burning through its liquid reserves to fund operations and development, thereby limiting its immediate financial flexibility and necessitating external capital raises to sustain its pipeline. Despite the negative operating performance, the balance sheet holds $5.31 million in cash against a relatively modest debt obligation of $258,025, creating a stark contrast in liquidity assets versus liabilities. The debt-to-equity ratio is calculated at 3.42, suggesting a highly leveraged capital structure where equity is used as the primary buffer against the small debt load, a strategy often seen in capital-intensive biotech firms before profitability is achieved. Furthermore, the current ratio is an impressive 7.53, which signifies an extremely strong short-term liquidity position where current assets far exceed current liabilities, providing a safety net against immediate solvency concerns despite the cash burn rate. However, the return metrics paint a challenging picture of management effectiveness, with a return on equity of -136.1% and a return on assets of -55.2%, indicating that the company is currently destroying value relative to its shareholders' investment and its total asset base.

Waarderingsbeoordeling

Valuation multiples for Nutriband Inc. are largely absent due to the company's unprofitability, as the trailing P/E and forward P/E ratios are both unlisted. The absence of a positive earnings denominator means that traditional earnings-based metrics cannot be applied to gauge the expected earnings trajectory, forcing reliance on asset-based metrics instead. The price-to-book ratio is recorded at 1.85, indicating that the market values the company at nearly twice its net book value, which may reflect intangible assets like intellectual property or the potential future value of the AVERSA fentanyl product that is not yet captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unlisted, further limiting the ability to compare the company's valuation against peers on a revenue or enterprise value basis. The stock price has exhibited significant volatility over the last year, trading between a 52-week low of $0.80 and a 52-week high of $4.50. Without a specific current share price provided to calculate the exact percentage, the trading range demonstrates a wide band of investor sentiment fluctuation, typical of speculative small-cap biotechnology stocks. The beta value is 1.93, which reveals that the stock's price volatility is substantially higher than that of the broader market, moving nearly twice as much as the benchmark index during periods of market stress or rally.

Growth & Income

The company experienced a revenue decline of -46.4% year-over-year, while earnings growth is effectively unavailable due to the lack of prior year comparative profitability. This contraction in revenue suggests a potential loss of market share, supply chain disruptions, or a strategic shift in focus that is impacting the top line, while the negative earnings growth aligns with the company's overall unprofitable status. Since the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for sustainability; consequently, the firm reinvests all available earnings—or rather, all available cash and financing—directly back into the business to fund its R&D pipeline and operational expansion. The overall growth and income profile is characterized by negative revenue momentum and zero income generation, presenting a high-risk, non-income generating asset that relies entirely on future product approvals and commercial success to reverse its current financial trajectory.